BCM
ZYME icon

Bayesian Capital Management’s Zymeworks ZYME Stock Holding History

Bayesian Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,768
Closed -$146K – 1068
2022
Q3 		$146K Sell
23,768
-30,600
-56% -$184K 0.03% 554
2022
Q2 		$288K Buy
+54,368
New +$329K 0.05% 497

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bayesian Capital Management's ZYME Position: Q4 2022 in Review

Bayesian Capital Management sold out of Zymeworks (ZYME) in Q4 2022, closing a stake of 23,768 shares — an estimated $146K sold.

Bayesian Capital Management first reported a position in ZYME in Q2 2022 and held it in 2 quarters. The position peaked at $288K in Q2 2022. 96 funds tracked by Wall St. Rank hold ZYME as of Q4 2022.

  • Bayesian Capital Management reported no remaining Zymeworks position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 23,768 Zymeworks shares in Q4 2022, an estimated $146K.
  • Bayesian Capital Management first reported a position in Zymeworks in Q2 2022 and held it in 2 quarters.
  • Bayesian Capital Management's Zymeworks position peaked at $288K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Zymeworks as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.